Mechanistic description
This hypothesis proposes that targeted modulation of microglial synaptic pruning activity can restore optimal functional connectivity patterns in diseased neural networks. Microglia express complement receptor 3 (CR3) and fractalkine receptor (CX3CR1) which mediate activity-dependent synaptic elimination through complement tagging of synapses marked by C1q and C3. In pathological conditions, aberrant microglial activation leads to excessive or insufficient synaptic pruning, disrupting functional network topology and information processing efficiency. By pharmacologically or genetically modulating CX3CR1 signaling or complement cascade components, we can fine-tune microglial pruning behavior to selectively eliminate weak or maladaptive synapses while preserving functionally important connections. This approach targets the dynamic remodeling of synaptic connectivity rather than structural white matter integrity, focusing on optimizing signal transmission patterns and network efficiency metrics derived from functional neuroimaging. The intervention would involve CX3CR1 agonists or antagonists, complement inhibitors, or microglial phenotype modulators administered during critical periods of network reorganization. Success would be measured through functional connectivity analyses, graph theory metrics of network efficiency, and behavioral assessments of cognitive function, rather than diffusion tensor imaging of white matter tracts.
Evidence for (5)
Myelin breakdown is an early, underrecognized feature of AD pathophysiology
Hub regions connected by long-range white matter tracts that are particularly vulnerable
Clemastine promotes OPC differentiation and remyelination in cuprizone and EAE models
Siponimod (Mayzent) FDA-approved for secondary progressive MS
Network-level changes include reduced white matter integrity measurable by diffusion MRI
Evidence against (5)
Myelin changes in AD may be secondary to axonal degeneration - primary vs secondary unresolved
White matter hyperintensities correlate with vascular pathology, not primary OPC dysfunction
Clemastine not advanced to AD clinical trials - off-target antihistamine effects
Siponimod failed in secondary progressive MS - S1P modulation insufficient for established myelin pathology
Aged human OPCs have substantially reduced differentiation capacity vs young animals